Preventive human papillomavirus vaccination

Sexually Transmitted Infections

Volumn 78, Issue 1, 2002, Pages 4-6

  Lehtinen, M ^a   Dillner, J ^a  

^a Department of Infectious Disease Epidemiology ^*  (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; CHIMERIC PROTEIN; HEPATITIS B VACCINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; VIRUS PROTEIN; VIRUS VACCINE;

CANCER INCIDENCE; CARCINOGENESIS; CYTOTOXIC T LYMPHOCYTE; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG SAFETY; IMMUNOGENICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; TRANSCRIPTION REGULATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRION; VIRUS CAPSID; VIRUS LOAD; VIRUS PARTICLE; VIRUS REPLICATION; WART VIRUS;

FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 0036194902     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.78.1.4     Document Type: Short Survey

References (19)

1. Estimates of the worldwide incidence of 25 major cancers in 1990
2. Human papillomavirus type 16 infection, subsequent risk for cervical neoplasia and associated population attributable fraction. A systematic review
3. Prospective seroepidemiological evidence that human papillomavirus type 16 infection is a risk factor for oesophageal squamous cell carcinoma
4. Prospective seroepidemiological study of the role of human papillomavirus in non-cervical anogenital cancers
5. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck
6. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine
7. Developing HPV virus-like-particle vaccines to prevent cervical cancer: A progress report
8. Identification of the alpha (6) integrin as a candidate receptor for papillomaviruses
9. Immunological analyses of human papillomavirus capsids
10. Efficacy of preventive HPV vaccination
11. HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination
12. Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications
13. Nationwide vaccination: A success story in Taiwan
14. Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens
15. A systematic review of the role of human papillomavirus testing within a cervical screening programme
16. Neutralizing antiviral antibody responses
17. Prospects for phase III-IV HPV vaccination trials in the Nordic countries and in Estonia
18. Assessing quality of controlled clinical trials
19. Public health paradoxes and the epidemiological impact of an HPV vaccine